Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Indo US Bio-Tech Ltd (INDOUS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 541304 NSE: INDOUS Agriculture | Small Cap | Indo US Bio-Tech Share Price
₹75.33 3.33 (4.63%)
As on 14-Oct'26 16:59
Indo US Bio-Tech Ltd (INDOUS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 541304 NSE: INDOUS Agriculture | Small Cap | Indo US Bio-Tech Share Price
₹75.33 3.33 (4.63%)
As on 14-Oct'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹144 Cr.
Current Price
₹75.3
52-Week Low / High
₹71 / 159
TTM EPS
₹5.7
TTM Sales
₹113 Cr.
Book Value per Share
₹47.7
P/E Ratio
12.60
Lower than its 5-year historical median
Industry PE
15.7
Price to Book (P/B)
1.51
Lower than its 5-year historical median
Price to Sales (P/S)
1.28
Lower than its 5-year historical median
EV/EBITDA
11.18
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
15.34%
Outperforms industry median
Return on Capital Employed (ROCE)
14.51%
Outperforms industry median
Return on Assets (ROA)
11.42%
Operating Profit Margin
18.2%
Net Profit Margin
11.88%
Gross Profit Margin
13.4%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
42.56%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-10.14%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-19.36%
Asset Quality
Promoter Holding
68.29%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹76 Cr.
Equity
₹20.1 Cr.
Face Value
₹10
All Time Low / High
₹12.85 / 386.00
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat UndervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Indo US Bio-Tech Ltd a good quality company?
Indo US Bio-Tech Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Indo US Bio-Tech Ltd performance compare with that of its Peers?
Revenue growth of Indo US Bio-Tech Ltd vs industry peers?
Indo US Bio-Tech Ltd revenue CAGR is 21.17%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Indo US Bio-Tech Ltd?
Promoters hold 68.29% of the Indo US Bio-Tech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Indo US Bio-Tech Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 10.21% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Indo US Bio-Tech Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 7.4% | 14.2% | 27.8% | 20.4% | 16.7% | 18.3% | 15.9% | 14.6% | 14.4% | 21.2% | - |
| Value Creation Index ⓘ | -0.5 | 0.0 | 1.0 | 0.5 | 0.2 | 0.3 | 0.1 | 0.0 | 0.0 | 0.5 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 19.1 | 24.5 | 29.6 | 35.5 | 39.8 | 40.1 | 50.1 | 61.7 | 72.8 | 104 | 113 |
| Sales YoY Gr. | - | 28.7% | 20.9% | 19.8% | 12% | 0.8% | 24.8% | 23.4% | 18% | 42.6% | - |
| Adj EPS ⓘ | 0.4 | 0.4 | 1.5 | 1.5 | 1.8 | 3.5 | 2.9 | 3.6 | 4.1 | 8.1 | 5.7 |
| YoY Gr. | - | 11.4% | 292.3% | -1.3% | 15.9% | 100% | -18.3% | 26.2% | 14.1% | 96.8% | - |
| BVPS (₹) ⓘ | 3.2 | 3.4 | 4.8 | 9.5 | 11.3 | 14.8 | 21.2 | 27.2 | 31.3 | 39.2 | 47.7 |
| Adj Net Profit ⓘ | 0.4 | 0.4 | 1.6 | 2.2 | 2.6 | 5.1 | 5.2 | 7.2 | 8.3 | 16.3 | 11 |
| Cash Flow from Ops. ⓘ | -2.6 | 0.1 | -0.9 | -3.2 | -0.8 | 0.2 | 2.9 | 0.5 | -4.6 | 1.4 | - |
| Debt/CF from Ops. ⓘ | -1.8 | 71.5 | -7.4 | -2 | -10.2 | 51 | 4.3 | 22.1 | -3.1 | 10.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 20.7% | 21.2% | 27.5% | 42.6% | ||||
| Adj EPS ⓘ | 41.8% | 35.9% | 41.5% | 96.8% | ||||
| BVPSⓘ | 32.2% | 28.3% | 22.7% | 25.2% | ||||
| Share Price | - | 11.2% | -26.5% | -41.8% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 11.7 | 11.7 | 37.2 | 23.3 | 16.8 | 26.9 | 17.3 | 15.5 | 14.1 | 23 | 13.2 |
| Op. Profit Mgn % ⓘ | 2.7 | 5.1 | 9.7 | 10.1 | 10 | 13.8 | 13.9 | 15.2 | 14.8 | 18.2 | 13.8 |
| Net Profit Mgn % ⓘ | 1.9 | 1.6 | 5.3 | 6.2 | 6.4 | 12.7 | 10.5 | 11.7 | 11.3 | 15.7 | 10.2 |
| Debt to Equity ⓘ | 1.4 | 1.4 | 1.3 | 0.5 | 0.5 | 0.5 | 0.3 | 0.2 | 0.2 | 0.2 | - |
| Working Cap Days ⓘ | 173 | 170 | 161 | 188 | 243 | 322 | 314 | 317 | 331 | 279 | 182 |
| Cash Conv. Cycle ⓘ | 84 | 84 | 102 | 146 | 173 | 214 | 255 | 271 | 295 | 265 | 127 |
Valuation of Indo US Bio-Tech - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 30 | 35 | 40 | 40 | 50 | 62 | 73 | 104 | 110 |
| Operating Expenses ⓘ + | 23 | 27 | 32 | 36 | 35 | 43 | 52 | 62 | 85 | 93 |
| Operating Profit ⓘ | 1 | 3 | 3 | 4 | 6 | 7 | 9 | 11 | 19 | 17 |
| Operating Profit Margin (%) | 5.1% | 9.1% | 9.6% | 10.0% | 13.8% | 13.8% | 15.2% | 14.8% | 18.2% | 15.4% |
| Other Income ⓘ + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest ⓘ | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 2 |
| Depreciation ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit Before Tax ⓘ | 1 | 2 | 3 | 3 | 4 | 5 | 7 | 9 | 17 | 14 |
| Tax ⓘ | 0 | 1 | 1 | 0 | -1 | 0 | 0 | 1 | 0 | 1 |
| Profit After Tax | 0 | 1 | 2 | 3 | 5 | 5 | 7 | 8 | 16 | 13 |
| PAT Margin (%) | 1.6% | 4.9% | 5.9% | 6.4% | 12.7% | 10.5% | 11.7% | 11.3% | 15.7% | 11.9% |
| Adjusted EPS (₹) | 0.4 | 1.4 | 1.4 | 1.7 | 3.5 | 2.9 | 3.6 | 4.1 | 8.1 | 6.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 3 | 5 | 14 | 16 | 22 | 39 | 54 | 63 | 79 | 93 | |
| Debt + | 5 | 6 | 5 | 8 | 11 | 10 | 10 | 13 | 13 | 36 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 4 | 5 | 2 | 8 | 9 | 2 | 1 | 4 | 1 | 0 | |
| Others Liabilities ⓘ | 0 | 1 | 2 | 2 | 2 | 4 | 3 | 3 | 4 | 4 | |
| Total Liabilities ⓘ | 12 | 17 | 24 | 35 | 43 | 55 | 69 | 84 | 97 | 133 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 1 | 2 | 1 | 1 | 2 | 6 | 7 | 7 | 10 | 11 | |
| CWIP ⓘ | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 4 | 0 | 1 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 5 | 6 | 11 | 9 | 12 | 23 | 27 | 52 | 71 | 100 | |
| Trade Receivables | 5 | 9 | 9 | 21 | 25 | 21 | 25 | 19 | 15 | 14 | |
| Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 6 | |
| Others Assets ⓘ | 1 | 0 | 1 | 2 | 2 | 3 | 8 | 1 | 1 | 1 | |
| Total Assets ⓘ | 12 | 17 | 24 | 35 | 43 | 55 | 69 | 84 | 97 | 133 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0 | -1 | -3 | -1 | 0 | 3 | 1 | -5 | 1 | -13 |
| Cash Flow From Investing Activity ⓘ + | -0 | 0 | -3 | -1 | -2 | -5 | -7 | 4 | -1 | -2 |
| Cash Flow From Financing Activity ⓘ + | 0 | 1 | 6 | 2 | 1 | 2 | 6 | 1 | -1 | 20 |
| Net Cash Flow ⓘ | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 1 | -1 | 6 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 11.74 | 34.36 | 22.21 | 16.74 | 26.87 | 17.34 | 15.51 | 14.08 | 23.03 | 15.34 |
| ROCE (%) | 14.24 | 27.84 | 20.35 | 16.65 | 18.3 | 15.86 | 14.62 | 14.42 | 21.15 | 14.51 |
| Asset Turnover Ratio | 1.95 | 2.05 | 1.74 | 1.36 | 1.03 | 1.02 | 1 | 0.95 | 1.15 | 0.96 |
| PAT to CFO Conversion(x) | N/A | -1 | -1.5 | -0.33 | 0 | 0.6 | 0.14 | -0.63 | 0.06 | -1 |
| Working Capital Days | ||||||||||
| Receivable Days | 79.40 | 86.60 | 92.80 | 137.90 | 207.90 | 164.90 | 133.90 | 109.70 | 59.80 | 47.50 |
| Inventory Days | 78 | 69.90 | 87 | 91.20 | 95.70 | 128.50 | 148.60 | 197.10 | 215.20 | 282 |
| Payable Days | 79.10 | 63.90 | 54.20 | 418.40 | 0 | -222.50 | 302.50 | -53.90 | 592.20 | 148.10 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Indo US Bio-Tech Ltd FAQs
The current trading price of Indo US Bio-Tech on 14-Oct-2026 16:59 is ₹75.33.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Oct-2026 the market cap of Indo US Bio-Tech stood at ₹144.4 Cr
The latest P/E ratio of Indo US Bio-Tech as of 13-Oct-2026 is 12.60.
The latest P/B ratio of Indo US Bio-Tech as of 13-Oct-2026 is 1.51.
The 52-week high of Indo US Bio-Tech is ₹158.8 and the 52-week low is ₹71.02.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Indo US Bio-Tech is ₹113 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Indo US Bio-Tech Ltd is a average quality company.
The key valuation ratios of Indo US Bio-Tech Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Indo US Bio-Tech Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Indo US Bio-Tech Ltd
Indo US Bio-Tech is a specialized agriculture seed company with its own research station, marketing network and seed production bases. The company was originally incorporated on February 04, 2004, with headquarter in Ahmedabad, Gujarat. Through sophisticated testing methods, the company ensures that seeds dispatched to different geographic locations perform well in the agro climatic & agroecological conditions of those locations.
The company’s Product Portfolio includes diversified variety of agriculture seeds namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds vegetables, pulses, crops like Tomato, Okra, Brinjal, Onion, Bit Root, cucumber, Bottle gourd, groundnut, mustard, Bajra, Wheat, Cumin, Coriander etc. Wide range of products allows the existing customers to source most of their product requirements from a single vendor and also enables the company to expand the business from existing customers, as well as address a larger base of potential new customers.
The company specializes in the Research and Development, production, Marketing and Sales of all types of Agriculture Seeds. The company is also engaged in educating the local farmers by field demonstration of various cultivated crops and giving proper guidance's to cultivation the crop which having better yield. The company has seed testing Laboratory.
Business area of the company
The company is engaged in the production and processing of commercial and vegetable seeds at various pieces of lands taken on lease from various growers/farmers spread over throughout India.
Products
- Vegetables Seeds
- Cotton Seeds
- Oil Seeds
- Spices Seeds
- Pulses Seeds
- Cereals Seeds
Milestones/ Awards/ Major events
- 2004: Company was incorporated under the Companies Act, 1956 with the name 'Pollucid Bio-Tech Private Limited'
- 2005: The name of the Company was changed to 'Pellucid Bio-Tech Private Limited'
- 2007: The name of Company was changed to 'Indo Us Bio-Tech Private Limited'
- 2009: The Company got registered as an ISO 9001:2008 Certified Company.
- 2010: Company had received Krushi Vigyan Seva Kharif Award by MP Government.
- 2011: Company gets approval for Research and Development (R&D) by Department of Scientific and Industrial Research Technology Bhavan, New Delhi (DSIR), the company was awarded with 'Excellence in Economic Development Award' for Quality Excellence.
- 2011: The company was awarded with All India Achievers Foundation Award.
- 2015: The company received Quality Mark Award
- 2018: The company was converted from Private Limited to Public limited.
- 2019: The company has been awarded by BSE Limited for being one of the top performers in SME Segment of BSE.
- 2019: The award has been received by Jagdish Ajudia, Managing Director of the Company from BSE Officials at Diwali Muhurat Trading function and Felicitation of Top Volume Performers Programme of BSE held on October 27, 2019, at Mumbai.
- 2024: Company entered into main board in NSE & BSE board
- 2024: Company received certificate of appreciation from SME empowering AwardE.
- 2025: Signed of a Memorandum of Understanding (MoU) with Sanskaram University, Jhajjar, Haryana - marking a new chapter of collaboration in agricultural innovation, research, and education.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
